Literature DB >> 16257408

C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003.

S Matthijs Boekholdt1, C Erik Hack, Manjinder S Sandhu, Robert Luben, Sheila A Bingham, Nicholas J Wareham, Ron J G Peters, J Wouter Jukema, Nicholas E Day, John J P Kastelein, Kay-Tee Khaw.   

Abstract

INTRODUCTION: Measurement of C-reactive protein (CRP) levels has been proposed as a useful marker to improve the prediction of future coronary artery disease (CAD) risk, but this notion has been challenged recently. METHODS AND
RESULTS: We performed a prospective case-control study among apparently healthy men and women. The odds ratio (OR) for future CAD incidence was 2.49 (95% CI=2.02-3.08, p for linearity <0.0001) unadjusted, and 1.66 (95% CI=1.31-2.12, p for linearity <0.0001), after adjustment for classical cardiovascular risk factors, for top versus bottom quartile of the CRP distribution. Notably, the risk factor adjusted predictive value was substantially stronger for fatal CAD (OR=2.92, 95% CI=1.83-4.67, p for linearity <0.0001) than for non-fatal CAD (OR=1.25, 95% CI=0.93-1.66, p for linearity=0.06). CRP levels were among the strongest predictors of CAD incidence and mortality. CRP levels remained a statistically significant predictor of future CAD, even after adjustment for the Framingham risk score.
CONCLUSIONS: In this British cohort with risk factor levels representative of a contemporary Western population, CRP concentration was among the strongest predictors of CAD incidence and mortality. We suggest that current guidelines on CRP measurement in clinical practice should be based on contemporary and representative populations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16257408     DOI: 10.1016/j.atherosclerosis.2005.09.023

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  45 in total

1.  The association between low-grade inflammation, iron status and nucleic acid oxidation in the elderly.

Authors:  Kasper Broedbaek; Volkert Siersma; Jon T Andersen; Morten Petersen; Shoaib Afzal; Brian Hjelvang; Allan Weimann; Richard D Semba; Luigi Ferrucci; Henrik E Poulsen
Journal:  Free Radic Res       Date:  2011-01-28

2.  Biomarkers: Coronary artery calcium is a better risk marker than hsCRP.

Authors:  Nikolaos Alexopoulos; Paolo Raggi
Journal:  Nat Rev Cardiol       Date:  2011-09-27       Impact factor: 32.419

3.  Endogenous reproductive hormones and C-reactive protein across the menstrual cycle: the BioCycle Study.

Authors:  Audrey J Gaskins; Machelle Wilchesky; Sunni L Mumford; Brian W Whitcomb; Richard W Browne; Jean Wactawski-Wende; Neil J Perkins; Enrique F Schisterman
Journal:  Am J Epidemiol       Date:  2012-02-03       Impact factor: 4.897

4.  Oral postmenopausal hormone therapy, C-reactive protein, and cardiovascular outcomes.

Authors:  Emily G Kurtz; Paul M Ridker; Lynda M Rose; Nancy R Cook; Brendan M Everett; Julie E Buring; Kathryn M Rexrode
Journal:  Menopause       Date:  2011-01       Impact factor: 2.953

5.  Assessing inflammatory status in cardiovascular disease.

Authors:  Dimitris Tousoulis; Charalambos Antoniades; Christodoulos Stefanadis
Journal:  Heart       Date:  2007-08       Impact factor: 5.994

Review 6.  The use of high-sensitivity assays for C-reactive protein in clinical practice.

Authors:  Kiran Musunuru; Brian G Kral; Roger S Blumenthal; Valentin Fuster; Catherine Y Campbell; Ty J Gluckman; Richard A Lange; Eric J Topol; James T Willerson; Milind Y Desai; Michael H Davidson; Samia Mora
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-08-19

Review 7.  Cardiac biomarkers: new tools for heart failure management.

Authors:  Navaid Iqbal; Bailey Wentworth; Rajiv Choudhary; Alejandro De La Parra Landa; Benjamin Kipper; Arrash Fard; Alan S Maisel
Journal:  Cardiovasc Diagn Ther       Date:  2012-06

Review 8.  Failure to consider the menstrual cycle phase may cause misinterpretation of clinical and research findings of cardiometabolic biomarkers in premenopausal women.

Authors:  Enrique F Schisterman; Sunni L Mumford; Lindsey A Sjaarda
Journal:  Epidemiol Rev       Date:  2013-09-15       Impact factor: 6.222

Review 9.  Update in general internal medicine.

Authors:  Toshiko Uchida; Stephen D Persell; David W Baker
Journal:  J Gen Intern Med       Date:  2009-10-28       Impact factor: 5.128

10.  Validation of Biomarkers of CVD Risk from Dried Blood Spots in Community-Based Research: Methodologies and Study-Specific Serum Equivalencies.

Authors:  Laura B Samuelsson; Martica H Hall; Shakir McLean; James H Porter; Lisa Berkman; Miguel Marino; Grace Sembajwe; Thomas W McDade; Orfeu M Buxton
Journal:  Biodemography Soc Biol       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.